Planned
CFT8634-1101
A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects with Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator :
CV-GBLM-001
A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients with Surgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular Signature of Unmethylated Glioblastoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
PM1183-C-010-22
Randomized, Controlled, Open-label, Phase IIb /III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator :
Ongoing
There are currently no ongoing studies in our center.
Closed
There are currently no closed studies in our center.